Acute Myeloid Leukemia Testing Market

Global Acute Myeloid Leukemia Testing Market is expected to grow with a CAGR of 5.8% over the forecast period.

Acute Myeloid Leukemia Testing Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2020-2026– Increasing incidences and prevalence of acute myeloid leukemia is one of the major factors driving the growth of Global Acute Myeloid Leukemia Testing Market. 

Scope of Global Acute Myeloid Leukemia Testing Market Report-

Acute Myeloid Leukemia is a type of cancer in which the bone marrow makes and spread to other organs, a wide range of symptoms can develop due to the blast cells enter the central nervous system. Acute myeloid leukemia involves the body producing too many nonfunctioning, immature white blood cells. Acute leukemia develops suddenly, while chronic leukemia lasts for a long time and progresses gradually. The general symptoms of acute myeloid leukemia can be similar to those of the flu such as fatigue, breathlessness, sweating more than usual, pallor, skin that bruises easily, a fever and other. Blood tests are generally the first tests done to look for leukemia. Blood is taken from a vein in the arm. Leukemia starts in the bone marrow, so checking the bone marrow for leukemia cells is a key part of testing for it.

Global Acute Myeloid Leukemia Testing Market report is segmented on the basis of biomarker type, end-user and region & country level. Based upon biomarker type, the acute myeloid leukemia testing market is segmented into genetic acute myeloid leukemia (AML) biomarker, epigenetic acute myeloid leukemia (AML) biomarker and proteomic acute myeloid leukemia (AML) biomarker. Based upon end-user, market is divided hospitals, cancer diagnostic centers, research institutes and others.

The regions covered in this acute myeloid leukemia testing market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of acute myeloid leukemia testing sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Key Players for Acute Myeloid Leukemia Testing –

Global Acute myeloid leukemia testing report covers prominent player’s NeoGenomics Laboratories, Inc., QIAGEN, Invivoscribe, Inc., Illumina, Inc., ArcherDx, Inc., ARUP Laboratories, ASURAGEN, INC., Mayo Foundation for Medical Education and Research, Laboratory Corporation of America Holdings, Dr Lal PathLabs, F. Hoffmann-La Roche Ltd, Abbott Laboratories, Thermo Fisher Scientific Inc., Cancer Genetics Inc., SkylineDx B.V. and  others.

 News- 

Precipio Launched its Proprietary HemeScreen AML (Acute Myeloid Leukemia) Molecular Panel

September 22^nd, 2020; Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), launched its HemeScreen AML (Acute Myeloid Leukemia) panel both clinically in its CLIA laboratory, and as part of its HemeScreen product offering. This new panel expands the HemeScreen offering for reference laboratories and physician office laboratories, enabling them to provide improved patient care through faster turnaround time.

Advancement in Pharmacology and Molecular Biology to Promote Drug Development is one of the Major Factors Driving the Global Acute Myeloid Leukemia Testing Market.

Rapidly increasing incidences and prevalence of acute myeloid leukemia is of the major factors driving the growth of global acute myeloid leukemia testing market. According to American Cancer Society; it is estimated that for leukemia in the United States for 2020 are about 60,530 new cases of leukemia (all kinds) and 23,100 deaths from leukemia. Increasing need of advanced therapeutics is also a high-impact rendering driver of this market. In addition, increasing geriatric population base and growing unmet healthcare needs are also expected to boost the market growth further. However, stringent regulations on drugs and complications related to chemotherapy may hamper the market growth within the forecast period. In spite of that, increasing investment in research and development and technological advancement may create the number of opportunities for the further growth of the market.

North America is expected to Dominate the Global Acute Myeloid Leukemia Testing Market.

North America is expected to dominate the global acute myeloid leukemia testing market. Advanced healthcare infrastructure, rising need of targeted therapies, huge investment in the development of drugs are some of the major factors responsible for market growth in this region within the forecast period. In addition, increasing technological advancement in healthcare sector and increased awareness about genetic testing are also fostering the market growth in this region. According to American Cancer Society’s estimates for leukemia in the United States for 2020 are around 19,940 new cases of acute myeloid leukemia. Asia pacific is becoming an emerging market for myeloid leukemia testing due to the increasing awareness about acute myeloid leukemia testing in this region. Increasing inclination towards therapies such as targeted therapies resulting in low collateral damage and stronger efficacy is also supplementing the market growth in this region. For example, according to MBCV In 2017, there were 11,923 combined new cases of leukemia, lymphoma and myeloma in Australia.

Key Benefits for Global Acute Myeloid Leukemia Testing Market Report-

• Global acute myeloid leukemia testing market report covers in depth historical and forecast analysis.
• Global acute myeloid leukemia testing market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.
• Global acute myeloid leukemia testing market report helps to identify opportunities in market place.
• Global acute myeloid leukemia testing market report covers extensive analysis of emerging trends and competitive landscape.

Acute Myeloid Leukemia Testing Market Report Coverage

Report Analysis

Details

Years :	2019	Market Size in 2019:	US$ XX Billion
Market Historical Analysis:	2015-2019	Forecast Analysis:	2020-2026
Forecast Period CAGR %:	5.8%	Market Size Expected to reach in 2026:	US$ XX Billion
Pages:	200	Tables, Charts & Figures:	169
Top Companies:	NeoGenomics Laboratories, Inc., QIAGEN, Invivoscribe, Inc., Illumina, Inc., ArcherDx, Inc., ARUP Laboratories, ASURAGEN, INC., Mayo Foundation for Medical Education and Research, Laboratory Corporation of America Holdings, Dr Lal PathLabs, F. Hoffmann-La Roche Ltd, Abbott Laboratories, Thermo Fisher Scientific Inc., Cancer Genetics Inc., SkylineDx B.V. and  others
Market Segmentation:	Biomarker Type, End-User
Regional Analysis:	North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa

Global Acute Myeloid Leukemia Testing Market Segmentation:

By Biomarker Type:

• Genetic Acute Myeloid Leukemia (AML) Biomarker
• Epigenetic Acute Myeloid Leukemia (AML) Biomarker
• Proteomic Acute Myeloid Leukemia (AML) Biomarker

By End-User:

• Hospitals
• Cancer diagnostic Centers
• Research Institutes
• Others

Regional & Country Analysis

North America

• U.S.
• Mexico
• Canada

Europe

• UK
• France
• Germany
• Italy

Asia Pacific

• China
• Japan
• India
• Southeast Asia

South America

• Brazil
• Argentina
• Columbia

The Middle East and Africa

• GCC
• Africa
• Rest of Middle East and Africa